Aarti Pharmalabs
Hyderabad, India· Est.
India‑based CDMO delivering FDA‑approved API and drug substance manufacturing with a focus on oncology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
India‑based CDMO delivering FDA‑approved API and drug substance manufacturing with a focus on oncology.
Oncology
Technology Platform
Flow chemistry scale‑up from lab to manufacturing combined with backward‑integration of raw material supply, enabling efficient production of high‑potency small‑molecule APIs.
Opportunities
Rising global demand for outsourced high‑potency oncology API manufacturing and the company's advanced flow chemistry platform present strong growth potential.
Risk Factors
Regulatory compliance challenges, raw‑material price fluctuations, and intense competition from other CDMOs could impact margins and market share.
Competitive Landscape
APL competes with Indian CDMOs such as Sun Pharma Advanced Research Institute and global players like Lonza; its differentiation lies in flow chemistry expertise and comprehensive regulatory certifications.